Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07643974 · ClinicalTrials.gov registry record · Early Phase 1

Coupled Gentamicin-Lactobacillus Rhamnosus in NLUTD

A Early Phase 1 study, sponsored by Medstar Health Research Institute.

Not yet
Registry status
Early Phase 1
Development phase
48
Enrollment target

NCT07643974 is a Early Phase 1 study that has not yet begun recruiting, run by Medstar Health Research Institute. The registered enrollment target is 48 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07643974, a Early Phase 1 study, has not yet begun recruiting, sponsored by Medstar Health Research Institute.

NOT YET RECRUITING
Registry status
Early Phase 1
Development phase
48 participants
Enrollment target

Study Summary

The main objective of the proposed research study is to determine in men and women with spinal cord injury/disease and neurogenic bladder whether the dose of coupled gentamicin \& Lactobacillus rhamnosus GG affects the recolonization of the bladder, and whether the rate of success differs by sex. Secondary objectives include determining whether that recolonization lasts 7, 14, or 28 days; and safety of the coupled gentamicin \& Lactobacillus instillations.

Interventions

  • DRUG Gentamicin
  • DRUG Lactobacillus Rhamnosus GG

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2026-06
Est. Completion 2027-09
Phase Early Phase 1

Sponsor

Medstar Health Research Institute

115 total trials

What the Registry Record Tells You About NCT07643974

The ClinicalTrials.gov registry entry for NCT07643974 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medstar Health Research Institute, which has 115 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Gentamicin is the first listed.

NCT07643974 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT07643974 about?

NCT07643974 is a clinical study titled "Coupled Gentamicin-Lactobacillus Rhamnosus in NLUTD". The main objective of the proposed research study is to determine in men and women with spinal cord injury/disease and neurogenic bladder whether the dose of coupled gentamicin \& Lactobacillus rhamnosus GG affects the recolonization of the bladder, and whether the rate of success differs by sex. Se...

What is the current status of trial NCT07643974?

This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 48 participants. The study started on 2026-06. Estimated completion is 2027-09.

What interventions are being tested in trial NCT07643974?

The interventions under investigation include: Gentamicin (DRUG), Lactobacillus Rhamnosus GG (DRUG).

Who is sponsoring clinical trial NCT07643974?

This trial is sponsored by Medstar Health Research Institute, which has 115 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.